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Our patient likely had rickettsial 
infection acquired in Honduras. We 
present this case to alert clinicians to 
consider the diagnosis of rickettsial in-
fections in the Americas, even if infec-
tions have not been previously docu-
mented in a specific country or region. 
Because rickettsial infections can be 
severe and are treatable, the clinician 
should consider rickettsial infections 
in returned travelers with compatible 
clinical findings. Our case also dem-
onstrates the potential role of travel-
ers as sentinels of emerging infectious 
diseases.
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KI and WU  
Polyomaviruses in 
Patients Infected 
with HIV-1, Italy
To the Editor: Before 2007, two 
human polyomaviruses were known to 
infect humans: BK virus and JC virus 
(1,2). Recently, 2 novel polyomavi-
ruses, KI polyomavirus (KIPyV) and 
WU polyomavirus (WUPyV), were 
identified in the respiratory secretions 
of children with signs of acute respira-
tory signs (3,4); little evidence exists 
to suggest that these viruses are caus-
ative agents of respiratory tract disease 
(5). To determine the prevalence of 
WUPyV and KIPyV in the plasma of 
HIV-1–infected patients, we screened 
62 persons who were HIV-1 positive 
by using PCR to detect the 2 viruses. 
We also conducted phylogenetic anal-
ysis of the identified strains.
Plasma specimens were collected 
at Istituto di Ricovero e Cura a Carat-
tere Scientifico Instituto Fisioterapico 
Ospetaliere–San Gallicano Institute 
and Tor Vergata University Hospital, 
Rome, Italy, from April 2005 through 
September 2008. Patients were adults 
(37–54 years of age, median age 45.5 
years) and were being treated with 
antiretroviral drugs. HIV-1 viral load 
determination, CD4+ counts, and 
HIV-1 genotyping were performed as 
part of the routine investigation. Plas-
ma viremia levels ranged from <50 
to 2,877,764 copies/mL, and CD4+ 
counts ranged from 150 to 1,218. 
Most patients (64.5%) were infected 
by HIV-1 subtype B. Other subtypes 
found were F, G, and C.
Total DNA was extracted from 0.2 
mL of plasma by using the QIAamp 
DNA Mini Kit according to the man-
ufacturer’s instruction (QIAGEN 
S.p.A., Milan, Italy) and then stored 
at –80ºC until analysis. KIPyV and 
WUPyV PCR screening was carried 
out as described (3,4). Positive iso-
lates were reamplified with primers 
encompassing the N-terminal part of 
the large T antigen (T-Ag) and almost 
the entire small t antigen (t-Ag) genes. 
KIPyV was amplified as described (6), 
and, for WUPyV, the primers were 
FWUV4460 5 ′-ACTGAGACCAC-
CAGTAATCCCAG-3 ′ (4460–4482 
nt) and RWUV5200 5 ′-AAGCAGAG-
GGCCTTGCTGAGGCG-3 ′ (5200–
5178 nt). The thermal cycling profile 
was 1 cycle at 94ºC for 10 min and 
then 40 cycles at 94ºC for 30 s, at 65ºC 
for 30 s, and at 72ºC for 60 s. The am-
plified t-Ag fragments were sequenced 
as described (6). The obtained se-
quences (KIV-RM21, KIV-RM22, and 
WU-IT3) were submitted to GenBank 
(accession nos. FJ842112–FJ842114) 
and matched against all deposited 
sequences (www.ncbi.nlm.nih.gov/
BLAST). ClustalX software (http://
bips.u-strasbg.fr/fr/documentation/
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clustalx/#g) was used to obtain align-
ment with a set of KIPyV and WUPyV 
isolates from Italy (6,7) (accession 
nos. FJ389513–FJ389516, FJ594120–
FJ594126, FJ594118, FJ594119, 
FJ804123, FJ811519–FJ811524, 
FJ824854, and FJ821706) and proto-
type strains for KIPyV (EF127906, 
EF127908, and EF520288) and for 
WUPyV (EF444549–EF444554, 
EU711054–EU711058, EU296475, 
EU358768, and EU358769). Align-
ment was manually edited with the 
Bioedit software (www.mbio.ncsu.
edu/BioEdit/bioedit.html) (6). Posi-
tions containing gaps were removed 
from the final alignment. For our 
dataset, the best fitting nucleotide sub-
stitution model was tested with a hi-
erarchical likelihood ratio test follow-
ing the strategy described (6),which 
used a neighbor-joining (NJ) base 
tree with LogDet-corrected distances 
(http://paup.csit.fsu.edu/about.html). 
Maximum-likelihood (ML) trees were 
then inferred with the selected model 
and ML-estimated substitution param-
eters. The heuristic search for the ML 
tree was performed by using an NJ tree 
as starting tree and the tree–bisection-
reconnection branch-swapping algo-
rithm. NJ trees were also estimated 
by using pairwise distances inferred 
by ML with the best fitting nucleotide 
substitution model. Calculations were 
performed by using PAUP* 4.0b10 
(http://paup.csit.fsu.edu/about.html) 
(6). Statistical support for internal 
branches in the NJ trees was obtained 
by bootstrapping (1,000 replicates) 
and with the ML-based, zero–branch-
length test for the ML trees (6).
Of 62 plasma specimens screened, 
PCR detected KIPyV in 2 (3.2%) and 
WUPyV in 1 (1.6%). All 3 patients 
were infected by HIV-1 subtype B. 
Phylogenetic analysis of the t-Ag of 
the 3 isolates showed that KIV-RM21 
and KIV-RM22 are not closely re-
lated to the KIPyVs isolated in Italy 
from feces (KIV-RM5 to KIV-RM11), 
respiratory tract (KIV-RM1 to KIV-
RM4), and tonsils (KIV-RM12 to KIV-
RM20), nor are they related to those 
previously identified (6,7). Similarly, 
WUV-IT3 was not related to WUV-
IT1 or WUV-IT2 nor to WUPyVs 
identified in stool and respiratory tract 
secretions (Figure).
To date, KIPyV  and WUPyV have 
been detected in respiratory secretions 
and stool and serum specimens from 
pediatric patients with acute respira-
tory symptoms and have been found 
in respiratory tissue of adults and chil-
dren (3,4,6,8). Few data are available 
on the detection and reactivation of 
these novel polyomaviruses in immu-
nocompromised patients (9,10). In this 
study, KIPyV and WUPyV sequences 
were found in 3.2% and 1.6% of 
HIV-1–infected patients, respectively. 
None of the patients had respiratory 
symptoms, so the presence of the 2 vi-
ruses in plasma raises the question of 
whether they play a pathogenic role in 
immunocompromised patients.
Molecular analysis of the KIPyV 
and WUPyV identified in plasma 
showed that these polyomaviruses 
were not closely related to strains 
identified previously in other countries 
nor to the KIPyVs and WUPyVs iden-
tified in Italy in stool, respiratory tract 
tissue, and tonsils. Whether this differ-
ence reflects a tropism of some strains 
for a particular tissue or organ remains 
to be established. Further studies are 
needed to clarify the possible patho-
Figure.	Unrooted	phylogenetic	tree	showing	analysis	of	KI	(KIV-RM21,	KIV-RM22)	and	WU	
(WUV-IT3)	polyomaviruses	(KIPyVs,	WUPyVs,	respectively)	identified	in	the	plasma	of	HIV-
1–positive	patients.	The	identified	strains	are	indicated	in	boldface,	and	the	phylogenetic	
analysis	refers	to	the	small	t	region.	The	other	polyomaviruses	shown	in	the	figure	are	the	
KIPyVs	(KIV-RM1	to	KIV-RM20)	and	WUPyVs	(WUV-IT1	and	WUV-IT2)	identified	in	Italy	
in	previous	 studies	 (6,7)	 and	 the	prototype	 strains	 for	KIPyV	 (GenBank	accession	nos.	
EF127906,	 EF127908,	 EF520288)	 and	WUPyV	 (GenBank	 accession	 nos.	 EF444549–
EF444554,	 EU711054–EU711058,	 EU296475,	 EU358768,	 and	 EU358769).	 GenBank	
accession	 numbers	 for	 all	 virus	 strains	 are	 shown	 in	 parentheses.	 Multiple	 nucleotide	
sequence	 alignments	were	 performed	 by	 using	ClustalX	 software	 (http://bips.u-strasbg.
fr/fr/documentation/clustalx/#g),	and	 the	phylogenetic	 tree	was	constructed	by	using	 the	
neighbor-joining	algorithm	with	LogDet-corrected	distances	(http://paup.csit.fsu.edu/about.
html)	(8).	An	asterisk	(*)	beside	a	branch	represents	significant	statistical	support	for	the	
clade	 subtending	 that	 branch	 (p<0.001	 in	 the	 zero-branch–length	 test)	 and	 bootstrap	
support	>75%.	Scale	bar	indicates	nucleotide	substitutions	per	site.
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genic role of KIPyV and WUPyV in 
immunocompromised patients.
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Extreme Drug  
Resistance in 
Acinetobacter  
baumannii  
Infections in  
Intensive Care 
Units, South Korea
To the Editor: Acinetobacter 
spp. have emerged as a cause of 
nosocomial infections, especially in 
intensive care units (ICUs). In South 
Korea, Acinetobacter spp. was ranked 
as the third most frequently found 
pathogen in ICUs (1). With the emer-
gence of multidrug-resistant (MDR) 
or pandrug-resistant (PDR) isolates, 
few drugs are now available to treat 
MDR or PDR Acinetobacter infec-
tions; polymyxins are the only thera-
peutic option in many cases (2). Cur-
rent polymyxin resistance rates among 
Acinetobacter isolates are low world-
wide (3). We report the emergence of 
extreme drug resistance (XDR) in A. 
baumannii isolates from patients in 
ICUs of Samsung Medical Center in 
Seoul, South Korea. These isolates 
were resistant to all tested antimicro-
bial drugs, including polymyxin B and 
colistin, to which PDR isolates are 
normally susceptible.
Sixty-three nonduplicate Acine-
tobacter spp. isolates were collected 
from the ICUs from April through No-
vember 2007. Species identification 
was performed based on partial RNA 
polymerase β-subunit gene sequences, 
amplified rDNA restriction analysis, 
and the gyrase B gene–based multi-
plex PCR method (3). Forty-four iso-
lates were identified as A. baumannii: 
9 as genomic species 3, six as genomic 
species 13TU, 2 as A. baumannii-like 
species, and 1 each as A. junnii and ge-
nomic species 10.
In vitro susceptibility testing was 
performed and interpreted by using the 
broth microdilution method according 
to the Clinical and Laboratory Stan-
dards Institute guidelines (4). Colistin 
and polymyxin B resistances were de-
fined as MIC >4 mg/L (4). MDR was 
defined as characterized by resistance 
to >3 classes of antimicrobial drugs, 
and PDR was defined as characterized 
by resistance to all antimicrobial drugs, 
regardless of colistin and polymyxin 
B susceptibility. XDR was defined as 
resistance to all antimicrobial drugs. 
Multilocus sequence typing (MLST) 
and pulsed-field gel electrophoresis 
(PFGE) were performed for all PDR 
isolates according to previously de-
scribed methods (5,6). Genes encod-
ing oxacillinases, such as those classi-
fied as OXA-23-like, OXA-24/40-like, 
OXA-51-like, and OXA-58-like, were 
detected as previously described (7). 
PCR and sequence analyses were per-
formed to detect and characterize the 
other antimicrobial resistance genes, 
according to methods reported (8).
